Concepedia

Clinical Characteristics, Outcome, and Therapeutic Effect of Tafamidis in Wild-Type Transthyretin Amyloid Cardiomyopathy

Seiji Takashio, Mami Morioka, Masanobu Ishii, Kei Morikawa, Kyoko Hirakawa, Shinsuke Hanatani, Fumi Oike, Hiroki Usuku, Masafumi Kidoh, Seitaro Oda,

ESC Heart Failure · 2023 · 45 citations · 25 references

DOIFull text

Open access

Abstract

The prognosis of patients with ATTRwt-CM treated with tafamidis was more favourable than that of untreated patients. Patient stratification combined with biomarkers (hs-cTnT, BNP, and eGFR) predicted clinical outcomes. hs-cTnT may be a useful biomarker for evaluating the therapeutic effect of tafamidis.

References

25

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Jeffrey H. Schwartz, Balarama Gundapaneni, Perry Elliott et al. · New England Journal of Medicine · 2018 · 2.6K citations · Full text

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis

Julian D. Gillmore, Rodney H. Falk, Giampaolo Merlini et al. · Circulation · 2016 · 1.9K citations · Full text

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction

Esther González-López, María Gallego‐Delgado, Gonzalo Guzzo-Merello et al. · European Heart Journal · 2015 · 1.1K citations · Full text

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

Pablo García‐Pavía, Claudio Rapezzi, Yehuda Adler et al. · European Heart Journal · 2021 · 1.1K citations · Full text

Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System

Martha Grogan, Christopher G. Scott, Robert A. Kyle et al. · Journal of the American College of Cardiology · 2016 · 705 citations

, , +7